Clinical value of biochemical indicator and hepatic fibrosis in differential diagnosis of patients with cirrhosis and chronic liver failure
10.3760/cma.j.issn.1008-6706.2019.22.009
- VernacularTitle: 常用生化酶谱和肝纤维化指标在肝硬化静止期与慢性肝功能衰竭鉴别诊断中的意义
- Author:
Zheen ZHANG
1
Author Information
1. Department of Infection, Zhoushan Hospital, Zhoushan, Zhejiang 316000, China
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
Liver failure;
Liver function tests;
Hyaluronic acid;
Laminin;
Collagen type Ⅳ;
Diagnosis, differential
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(22):2725-2728
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical value of biochemical indicator and hepatic fibrosis in differential diagnosis of patients with cirrhosis and chronic liver failure.
Methods:From December 2015 to December 2018, 30 patients with cirrhosis and 30 patients with chronic liver failure in Zhoushan Hospital were selected.The serum levels of ALT, AST, TBil, hyaluronic acid (HA), laminin (LN), PC-Ⅲ, collagen type Ⅳ(Ⅳ-C) were detected.
Results:The serum levels of ALT, AST and TBil in patients with cirrhosis were significantly lower than those in patients with chronic liver failure[(258.17±88.19)U/L vs.(818.37±375.83)U/L; (256.57±97.21)U/L vs.(738.63±329.68)U/L; (51.37±22.13)μmol/L vs.(157.27±85.60)μmol/L, t=-7.95, -7.68, -6.56, all P<0.01]. The serum levels of HA, LN, PC-Ⅲ and Ⅳ-C in patients with cirrhosis were significantly higher than those in patients with chronic liver failure[(433.10±214.39)μg/L vs.(81.56±27.80)μg/L; (157.67±52.60)μg/L vs.(66.06±24.06)μg/L; (126.63±35.24)μg/L vs.(70.96±19.71)μg/L; (162.26±53.93)μg/L vs.(76.13±27.90)μg/L, t=8.90, 8.67, 7.49, 7.76, all P<0.01]. When patients with chronic liver failure were set as state variable, AUC of ALT(0.973) was the highest in ALT, AST, TBil.When patients with cirrhosis were set as state variable, AUC of HA(0.993) was the highest in HA, LN, PC-Ⅲ and Ⅳ-C.
Conclusion:ALT and HA are suitable for differential diagnosis of patients with cirrhosis and chronic liver failure.
